These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37331847)

  • 41. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
    Batlevi CL; Sha F; Alperovich A; Ni A; Smith K; Ying Z; Soumerai JD; Caron PC; Falchi L; Hamilton A; Hamlin PA; Horwitz SM; Joffe E; Kumar A; Matasar MJ; Moskowitz AJ; Moskowitz CH; Noy A; Owens C; Palomba LM; Straus D; von Keudell G; Zelenetz AD; Seshan VE; Younes A
    Blood Cancer J; 2020 Jul; 10(7):74. PubMed ID: 32678074
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.
    Giné E; Montoto S; Bosch F; Arenillas L; Mercadal S; Villamor N; Martínez A; Colomo L; Campo E; Montserrat E; López-Guillermo A
    Ann Oncol; 2006 Oct; 17(10):1539-45. PubMed ID: 16940035
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of age on clinical risk scores in follicular lymphoma.
    Alig S; Jurinovic V; Pastore A; Haebe S; Schmidt C; Zoellner AK; Dreyling M; Unterhalt M; Hoster E; Hiddemann W; Weigert O
    Blood Adv; 2019 Apr; 3(7):1033-1038. PubMed ID: 30940638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
    Buske C; Hoster E; Dreyling M; Hasford J; Unterhalt M; Hiddemann W
    Blood; 2006 Sep; 108(5):1504-8. PubMed ID: 16690968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The clinical applicability of current prognostic models in follicular lymphoma: A systematic review.
    Jelicic J; Stauffer Larsen T; Bukumiric Z; Andjelic B
    Crit Rev Oncol Hematol; 2021 Aug; 164():103418. PubMed ID: 34246773
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
    Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
    Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
    Gao F; Liu H; Meng X; Liu J; Wang J; Yu J; Liu X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Golchehre Z; Chavoshzadeh Z; He J; Zhang H; Wang X
    Br J Haematol; 2023 Sep; 202(6):1151-1164. PubMed ID: 37455019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting.
    van de Schans SA; Steyerberg EW; Nijziel MR; Creemers GJ; Janssen-Heijnen ML; van Spronsen DJ
    Ann Oncol; 2009 Oct; 20(10):1697-702. PubMed ID: 19549712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
    Blum KA; Polley MY; Jung SH; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD; Leonard JP; Bartlett NL
    Cancer; 2019 Oct; 125(19):3378-3389. PubMed ID: 31174236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.
    Annunzio K; Bhatta S; Hanel W; Zhao Q; Owen M; Rosen H; Voorhees TJ; Bond DA; Sawalha Y; Sigmund AM; Alinari L; Baiocchi RA; Maddocks KJ; Jones D; Christian B; Epperla N
    Hematol Oncol; 2024 May; 42(3):e3278. PubMed ID: 38726682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Follicular lymphoma: 2023 update on diagnosis and management.
    Jacobsen E
    Am J Hematol; 2022 Dec; 97(12):1638-1651. PubMed ID: 36255040
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serbian lymphoma study group: demografic characteristics of 257 patients with follicular lymphoma.
    Simonović O; Mačukanović-Golubović L; Andjelić B; Antić D; Mihaljević B
    Vojnosanit Pregl; 2015 Jun; 72(6):483-8. PubMed ID: 26226718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy.
    Kimby E; Lockmer S; Holte H; Hagberg H; Wahlin BE; Brown P; Østenstad B
    Br J Haematol; 2020 Dec; 191(5):738-747. PubMed ID: 32410260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma.
    Puckrin R; Chua N; Chin K; Peters A; Duggan P; Shafey M; Storek J; Jamani K; Owen C; Stewart D
    Br J Haematol; 2023 Apr; 201(2):319-325. PubMed ID: 36625160
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.
    Mozessohn L; Cheung MC; Crump M; Buckstein R; Berinstein N; Imrie K; Kuruvilla J; Piliotis E; Kukreti V
    Leuk Lymphoma; 2014 Nov; 55(11):2502-7. PubMed ID: 24450580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.
    Sorigue M; Mercadal S; Alonso S; Fernández-Álvarez R; García O; Moreno M; Pomares H; Alcoceba M; González-García E; Motlló C; González-Barca E; Martin A; Sureda A; Caballero D; Ribera JM; Sancho JM
    Hematol Oncol; 2017 Dec; 35(4):520-527. PubMed ID: 28156010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China.
    Gao F; Zhang T; Liu X; Qu Z; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Wang X; Zhang H
    Front Oncol; 2022; 12():863021. PubMed ID: 36185179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
    Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Life expectancy of young adults with follicular lymphoma.
    Conconi A; Lobetti-Bodoni C; Montoto S; Lopez-Guillermo A; Coutinho R; Matthews J; Franceschetti S; Bertoni F; Moccia A; Rancoita PM; Gribben J; Cavalli F; Gaidano G; Lister TA; Montserrat E; Ghielmini M; Zucca E
    Ann Oncol; 2015 Nov; 26(11):2317-22. PubMed ID: 26362567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.